Empaglifozin reduces death in heart failure patients with preserved ejection fraction
1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and ...
Tag: HFpEF (heart failure with preserved ejection fraction
Substantial prevalence of transthyretin amyloid cardiomyopathy present in patients with heart failure with preserved ejection fraction
1. Transthyretin amyloid cardiomyopathy was present in a substantial number of patients with heart failure with preserved ejection fraction and ...
Coronary artery disease common in hospitalized patients with heart failure with preserved ejection fraction
1. In this cohort study, 91% of patients with preserved ejection fraction heart failure had evidence of epicardial coronary artery ...
Relative risk of heart failure from traditional risk factors is greater in younger than in older adults
1. Hypertension, diabetes, smoking, atrial fibrillation, and previous myocardial infarction were associated with a higher risk of incident heart failure ...
#VisualAbstract: Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction
1. In this randomized controlled trial, heart failure with preserved ejection fraction (HFpEF) patients did not have improved exercise capacity ...
Neladenoson does not increase exercise capacity for heart failure with preserved ejection fraction
1. In this randomized controlled trial, heart failure with preserved ejection fraction (HFpEF) patients did not have improved exercise capacity ...